atai Life Sciences, a biotech company, agreed to acquire a 35.5% stake in Beckley Psytech, a psychedelic medicine company, for $50m. “Beckley Psytech and atai Life Sciences share a vision for the future of mental health treatment, and we are excited to join forces on the journey to develop effective, accessible, rapid-acting psychedelic medicines for people in need. Alongside the financial investment, we are optimistic about the numerous possible synergies of this collaboration, especially in developing digital tools to optimize patient support and planning for future commercialization. We look forward to exploring these in the coming months,” Cosmo Feilding Mellen, Beckley Psytech CEO.